U.S. Markets closed

CROSSJECT : boosts its US commercial development efforts

CROSSJECT boosts its US commercial development efforts

20 February 2017

             

CROSSJECT, (ISIN: FR0011716265; Mnemo: ALCJ), a specialty pharma developing a portfolio of New Therapeutic Entities for emergency auto-injection, is accelerating the implementation of its strategy for the United States (US).

CROSSJECT has set up several key activities:     

  • The brokering of Zeneo® Sumatriptan (severe migraines) potential partnerships for the US and Canada has been entrusted to a London-based advisory company, operating with a network of seasoned pharma executives across the US. This network has brokered over 50 pharma business development deals in the US over the past 10 years, with cumulated upfront payments in excess of USD 400 million;
     
  • For the regulatory process with the US Food and Drug Administration (FDA), CROSSJECT has appointed a Washington-based regulatory firm;
     
  • A commercial opportunity assessment for Zeneo® Midazolam (epileptic seizures) on the US market is being prepared by Bionest Partners, a life-sciences-focused consulting firm based in New-York and Paris. This type of assessments are used for business development activities.

Patrick Alexandre, CROSSJECT`s founder and CEO, declared: « « In line with our strategy, we are making sure we can capture the full value of our portfolio of emergency treatment drugs in the US, and sign the right licensing agreements in a near future. »
Contacts

     CROSSJECT
     Patrick Alexandre
      info@CROSSJECT.com

 
Investor relations
Actifin
Benjamin Lehari   +33 (0)1 56 88 11 25
blehari@actifin.fr

 

Press relations
Citigate Dewe Rogerson
Laurence Bault   +33 (0)1 53 32 84 78
laurence.bault@citigate.fr
   

About CROSSJECT  ·  www.CROSSJECT.com
CROSSJECT (ISIN: FR0011716265; Mnemo: ALCJ) is a specialty pharma developing and conceiving a portfolio of drug candidates for emergency situations (overdoses, acute migraines, epilepsy, temporary paralysis, anaphylactic chocks, etc.). With Zeneo®, its patented needle-free injection system, CROSSJECT provides efficiency to emergency situations by allowing simple drug self-administration.CROSSJECT is listed on Alternext (Euronext Paris) since February 2014
 Follow us on Twitter: @Crossject_

Disclaimer
Some of the statements contained in this press release constitute forward-looking statements. These statements constitute either expectations or goals and shall not be considered as future results or any other performance indicators. These statements involve risks and uncertainties, out of control of the company in certain cases, especially during a R&D process. A detailed description of these risks and uncertainties is to be found in the Document de Base of the company, available on its website (www.crossject.com)

CROSSJECT boosts its US commercial development efforts


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CROSSJECT via GlobeNewswire

HUG#2080232